Rising Incidence Of Cancer Cases Drives Growth In The Neoantigen Targeted Therapies Market: Core Growth Enabler in the Neoantigen Targeted Therapies Market, 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Neoantigen Targeted Therapies Industry Market Size Be by 2025?
There has been a notable expansion in the market size of neoantigen targeted therapies in the last few years. This market is projected to grow from $3.4 billion in 2024 to $4.72 billion in 2025, experiencing a compound annual growth rate (CAGR) of 38.7%. This significant growth during the historical period is largely due to developments in genomic sequencing, immunotherapy evolution, a better comprehension of tumor immunology, the clinical success of checkpoint inhibitors, and progress in molecular profiling.

What's the Long-Term Growth Forecast for the Neoantigen Targeted Therapies Market Size Through 2029?
The market size of neoantigen targeted therapies is poised for a dramatic increase in the coming years, anticipated to reach $16.01 billion by 2029, with a compound annual growth rate (CAGR) of 35.7%. The surge during this forecasted period is explained by advancements in bioinformatics, the broadening of precision medicine, development of neoantigen vaccines, strategies for therapeutic combinations, and biomarker validation. Foreseen trends during this forecasted span include management of neoantigen resistance, neoantigen-primed adoptive cell therapies, combined therapies based on neoantigen, incorporation of real-world data, and refined predictive models.

View the full report here:
https://www.thebusinessresearchcompany.com/report/neoantigen-targeted-therapies-global-market-report

What Are the Key Growth Drivers Fueling the Neoantigen Targeted Therapies Market Expansion?
The rise in cancer cases is anticipated to fuel the advancement of the neoantigen targeted therapies market. The term "incidence of cancer" refers to the tally of new cancer incidents in a specific demographic within a specified time frame. Neoantigen-targeted treatments are frequently used in tandem to treat various cancer forms. For example, the American Cancer Society (ACS), a voluntary health organization in the U.S., reported that in 2022 the country witnessed 1.9 million new instances of cancer which demonstrates a substantial hike compared to past years. Additionally, approximately 609,360 deaths were attributed to cancer in the U.S. in 2022, underlining the massive severity and influence of this ailment on people and their loved ones. Hence, the escalating rate of cancer incidents fuels the expansion of the neoantigen targeted therapies market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=11944&type=smp

What Are the Key Trends Driving Neoantigen Targeted Therapies Market Growth?
Key players in the neoantigen targeted treatments market are turning to strategic alliances to customize cancer treatments, looking to overcome constraints of present immunotherapy techniques in dealing with solid tumors. Strategic alliances involve businesses mutually benefiting by utilizing each other's assets and competencies. For instance, in January 2023, the German biotechnology firm BioNTech SE partnered with the UK Government to enhance personalized mRNA cancer immunotherapies. The aim of this cooperation is to provide personalized treatments to around 10,000 patients by 2030 and focuses on key areas such as development of cancer immunotherapies, infectious disease vaccine research, and establishment of a research and development center in Cambridge. The endeavor will make use of UK's clinical trial framework and health data resources to enhance patient enlistment and choose trial locations for BioNTech's mRNA therapies. The firm aims to kickstart its initial clinical trials in the UK later this year, with a concentration on cancer vaccines that might possibly be incorporated into standard treatment protocols if found effective.

How Is the Neoantigen Targeted Therapies Market Segmented?
The neoantigen targeted therapies market covered in this report is segmented -

1) By Type: Monotherapy, Combination Therapy
2) By Immunotherapy Type: DNA Or RNA-Based Vaccines, Protein-Based Vaccines, Dendritic Cell Vaccines, TIL-Based Therapies
3) By Target Disease Indication: Colorectal Cancer, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Bone Cancer, Gynecological Cancer
4) By Route Of Administration: Intradermal, Intravenous, Subcutaneous
5) By Application: Medical Research Institution, Hospital, And Clinic, Other Applications

Subsegments:
1) By Monotherapy: Individual Neoantigen-Targeted Treatments
2) By Combination Therapy: Neoantigen-Targeted Therapies Combined With Other Immunotherapies, Neoantigen-Targeted Therapies Combined With Chemotherapy, Neoantigen-Targeted Therapies Combined With Targeted Therapies

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=11944&type=smp

Which Companies Are Leading the Charge in Neoantigen Targeted Therapies Market Innovation?
Major companies operating in the neoantigen targeted therapies market include F. Hoffmann-La Roche AG, Merck and Co. Inc., Bristol Myers Squibb Company, Eli Lilly and Company, Kite Pharma Inc., Gilead Sciences Inc., Amgen Inc., Moderna Inc., BioNTech SE, Bavarian Nordic Inc., Advaxis Inc., Immatics NV, Precision Biologics Inc., Iovance Biotherapeutics Inc., Agenus Inc., Achilles Therapeutics Plc, Medigene AG, Gritstone Bio Inc., SQZ Biotechnologies Company, Aduro BioTech Inc., Inovio Pharmaceuticals Inc., Gradalis Inc., EpiVax Inc., ISA Pharmaceuticals BV, Vaxon Biotech SA, Ziopharm Oncology, Genocea Biosciences Inc., Cellular Biomedicine Group Inc., Immunovaccine Inc.

Which Regions Are Leading the Global Neoantigen Targeted Therapies Market in Revenue?
North America was the largest region in the neoantigen targeted therapies market in 2024. The regions covered in the neoantigen targeted therapies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=11944

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.